AG-120, also known as Ivosidenib, is a potential candidate for various IDH1 mutants and the only inhibitor which successfully entered into the phase III level of various clinical tests including Cholangiocarcinoma, Leukemia, Acute Myeloid Cancer, and solid tumors [27]. This evidence concerns the gene IDH1 and cholangiocarcinoma.